Truist Financial Corp Sells 8,062 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Truist Financial Corp reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 44,381 shares of the biopharmaceutical company’s stock after selling 8,062 shares during the quarter. Truist Financial Corp’s holdings in Regeneron Pharmaceuticals were worth $38,979,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in REGN. Meyer Handelman Co. lifted its position in shares of Regeneron Pharmaceuticals by 11.4% during the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock valued at $3,485,000 after buying an additional 435 shares in the last quarter. Stifel Financial Corp lifted its position in shares of Regeneron Pharmaceuticals by 12.2% during the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after buying an additional 3,385 shares in the last quarter. LPL Financial LLC lifted its position in shares of Regeneron Pharmaceuticals by 9.3% during the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after buying an additional 3,479 shares in the last quarter. Cavalier Investments LLC lifted its position in shares of Regeneron Pharmaceuticals by 88.6% during the 3rd quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock valued at $3,651,000 after buying an additional 2,084 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its position in shares of Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after buying an additional 1,221 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $883.20 on Monday. The stock’s fifty day moving average is $948.00 and its 200 day moving average is $894.45. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The firm has a market capitalization of $96.94 billion, a PE ratio of 25.42, a PEG ratio of 2.54 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the prior year, the firm posted $10.96 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares in the company, valued at approximately $17,540,472.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,022 shares of company stock worth $10,552,991. Company insiders own 8.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 20th. Finally, TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.